Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

2
Let Me Tell You Who Is Moving Off Of Oracle

24m seekingalpha
Amazon and Salesforce may leave Oracle by 2020 and 2023, setting a new precedence for Oracle migration.
MSFT ORCL CRM

8
Don’t Count Out These 5 Active Mutual Funds

5h investorplace
There’s a reason why the investment world has gone gaga for passive indexing and exchange-traded funds (ETFs). The biggest reason comes down to overall better returns. After all, most actively managed mutual funds and other investment vehicles with a human touch tend to lag the broader market. That’s partly due to their higher fee structure and inability to be fully invested.
SQ GOOGL GOOG CRM FTQGX

4
ServiceNow: Still Spending Heavily On Growth Despite Wide Moat

9h seekingalpha
However, new product offerings and high R&D and sales and marketing expenses suggest the company will not slow down.
DBX NOW WDAY CRM

32
3 Reasons to Sell Shopify

2018-08-17 investorplace
I’ve been very bullish on Shopify (NYSE:SHOP) for some time now. But even with SHOP stock having pulled back sharply of late, I’ll admit to having some second thoughts.
FB BABA SQ SHOP MU TWTR NVDA CRM ETSY EBAY

17
Walmart Has Become A Must-Own Stock - Cramer's Mad Money (8/16/18)

2018-08-17 seekingalpha - 1
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, August 16.
GOOS ANGI COST WMT CRM SIRI MTCH ALXN AAPL AEP DPZ

11
Sustainability And Disruption: Natural Twins

2018-08-15 seekingalpha
There is strong evidence that investment trends continue to favor those companies transforming the world for the better. We believe that only those firms committed to building a sustainable economy are likely to thrive in an environment that is rapidly evolving. Climate change, resource constraints, and aging and growing populations are some of the most complex megatrends humanity has faced and demand innovative and lasting solutions.
SAP MSFT ADSK JHG CRM ADBE

1
Buying Salesforce.com, A Portfolio Of Growth Products

2018-08-15 seekingalpha - 1
The company is a portfolio of growth products, and the SaaS model should help to keep revenues "sticky" while pushing margins up.
CRM

39
7 Momentum Stocks That Will Power Through 2018

2018-08-13 investorplace
Investors looking for long-term growth sometimes seek momentum stocks in an attempt to find significant gains amid all the market madness.
ALGN AMZN MA HRS ILMN ABMD CRM

85
Tracking Dan Loeb's Third Point Portfolio - Q2 2018 Update

2018-08-12 seekingalpha - 2
Dan Loeb's 13F portfolio value increased from $13.32B to $14.35B this quarter. The number of positions decreased from 40 to 38.
ATHTF STZ.B TWX CRM DOW DOV MELI PBF TPRE WP KDMN STZ UTX BKI TWC PVH DVMT FPAC.U GOOGL MSFT APY MHK TPNTF GRBK FB DOV.WI LEN NXPI PYPL NFLX BAX GOOG LEN.B MPC PAGS ADBE SPGI EGN MON ICE SHY CWH EA WYNN ANTM DWDP BID BLK V DHR ANTX

42
Why Salesforce.com (CRM) is Poised to Beat Earnings Estimates Again

2018-08-11 zacks - 1
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Salesforce.com (CRM - Free Report) , which belongs to the Zacks Computer - Software industry, could be a great candidate to consider.
REI CRM ADMP

0
Know This Momentum Pattern Trade In Salesforce Ahead Of Earnings

2018-08-08 seekingalpha
This phenomenon is not due solely to a bull market but rather persisted throughout the Great Recession as well, making it one of the few decade-long market-wide anomalies.
CRM

0
Is Salesforce Solidifying Its Succession Plan With New Co-CEO Appointment?

2018-08-08 247wallst
Salesforce.com Inc. (NYSE: CRM) is shuffling its deck of executives and making a fresh appointment at the top for its co-CEO position. It seems logical that this is also a move by the company to solidify its succession plan.
CRM

0
CRM / Salesforce.com, Inc. 8-K (Current Report)

2018-08-08 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CRM

88
10 Reasons Apple Hit $1 Trillion - Cramer's Mad Money (8/2/18)

2018-08-03 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, August 2.
BABA RDFN S WYNN TMUS XEC AAPL DOW SBUX MCD DWDP CRM

0
Tableau: Valuations Difficult To 'Visualize'

2018-07-30 seekingalpha
The company’s declining growth and increasing competition in the market do not justify such a lofty multiple.
DATA CRM

Related Articles

REPH: Recro Pharma Analysis and Research Report

15h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

15h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

16h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 79466L302